Do you have systemic lupus erythematosus (SLE)? Together with The Arthritis Society, we have developed a survey to help us create a patient input submission for Benlysta (Belimumab) for the Common Drug Review (CDR). The CDR is a program of the Canadian Agency for Drugs and Technology in Health (CADTH) and makes recommendations for listing medications to federal, provincial and territorial drug programs. The CDR is currently reviewing Benlysta (Belimumab) for the treatment of SLE.
Please take the survey and have your voice heard in the drug reimbursement review and decision-making process. It will take less than 15 minutes of your time and your views will be anonymous. If you have any questions, please contact firstname.lastname@example.org or email@example.com. Thank you for your contributions!